Kudin Sha: Karin Gwari da Ya Aiki a Lokacin da Ake Bukata
Allurar rigakafi galibi ba ta bada kariya sosai ga mutane masu shekaru sama da 65. Wani bincike da jami'ar Oxford ta jagoranta ya nuna cewa polyamine da ake samu a cikin hatsi, cuku mai tsufa da wake – spermidine – na iya taimakawa a lokacin da allura ta kasa yin tasiri. Fa'idar ta bayyana ne kawai a cikin mutanen da ba su amsa allurar a farko ba.
Binciken an wallafa shi a Aging Cell a shekarar 2026. Shi ne gwaji na farko, ƙarami, kuma an yi shi a matakin farawa. Haka kuma, shi ne ɗaya daga cikin ƙananan bayanai da suka tabo batun “autophagy supplement” a duniya.
Tsarin Binciken
- Tsari: gwaji na double‑blind, randomised, placebo‑controlled (pilot study)
- Masu halarta: mutane 40 masu lafiya, shekaru sama da 65
- Yanayi: an zaɓi su bayan sau na uku na allurar SARS‑CoV‑2
- Horarwa: 6 mg spermidine a rana, ana sha baki na makonni 13, a kan placebo
- Manufa ta farko: duba aminci da tasiri kan amsar allura
An samu karɓuwa mai kyau ga ƙarin. Masu binciken sun fito daga Jami'ar Oxford, Max‑Delbrück Center a Berlin, Jami'ar Graz da Cardiff University.
Me Ya Sa Allura Ke Kasa Aiki a Manyan Mutane?
Garkuwar jikin manya ba ta amsa allura da ƙarfi kamar yadda ake tsammani. Marubutan sun nuna cewa ƙwayoyin B da T na raguwa yayin da autophagy ke ƙasa, sannan immunosenescence da kumburin da ba a gani ba ke ƙaruwa.
Spermidine yana haifar da autophagy kuma yana rage immunosenescence a gwaje‑gwajen dabbobi, yayin da matakin sa ke raguwa da tsufa a mutane. Wannan ya sa shi ya zama zaɓi mai ma'ana a gwada a manya da suka riga sun yi rigakafi.
Sakamako #1: Alamar Senescence a Masu Rashin Amsa
Rashin amsa ga allura ya kasance gama gari a wannan rukuni. Kwayoyin lymphocytes na masu rashin amsa sun nuna:
- ƙaruwa a p16, alamar senescence da aka saba gani
- ƙaruwa a mTOR signalling
- γ‑H2AX+ DNA damage
Marubutan sun ba da shawarar cewa waɗannan alamu na iya taimakawa nan gaba wajen hango mutanen da za su kasa amsa allura. Wannan ra'ayi na buƙatar gwaje‑gwaje a manyan rukunai.
Sakamako #2: Spermidine Ya Mayar Da Alamar Senescence Kuma Ya Ƙara Immunity
A cikin masu rashin amsa, spermidine ya rage alamun senescence. Haka kuma ya ƙara sosai:
- sakin IgG na spike
- amsa daga memory B cells
- kariya daga neutralising antibodies
Mahimmancin sakamakon shine “musamman a cikin masu rashin amsa.” Ba a ga ƙaruwa a mutanen da suka riga su amsa allura ba. Don haka, spermidine ba ta zama ƙara garkuwar jiki gaba ɗaya ba.
Sakamako #3: Alamar Autophagy
Bayan an yi single‑cell RNA sequencing bayan magani, an ga ƙaruwa a fitarwa na TFEB targets da ƙwayoyin da suka shafi autophagy a B cells. TFEB shi ne babban mai kula da shirye‑shiryen lysosomal da autophagy. Wannan ya dace da ƙaruwa a autophagic flux, don haka ribar garkuwa ta bayyana a tsarin da aka yi hasashen, ba kawai yawan antibodies ba.
Bambanci: Kuskuren Memory na Spermidine
Spermidine a cikin mutane ba ta da cikakkiyar nasara a kowane yanayi. Gwajin SmartAge da ya gabata ya yi amfani da 0.9 mg/ran don inganta tunani a manya da ke da damuwa da ƙwaƙwalwa, inda ba a ga ƙara a ƙwaƙwalwa ba idan aka kwatanta da placebo.
Biyun ba su da alaƙa kai tsaye: biri ne (memory vs. rigakafi), rukuni da tsawon lokaci duk sun sha bamban. 6 mg ya fi 0.9 mg sosai – kusan sau 6.7. Shin ƙimar ce ke haifar da bambanci? Wannan tambaya na nan har yanzu, ba a ƙara ba.
Me Wannan Ke Nufi A Gare Ka?
- Kimar da aka gwada: 6 mg a rana, ana sha baki. Ba a gwada ƙima daban ba, don haka babu dalilin cewa ƙarin zai fi.
- Tsawon lokaci: makonni 13, bayan allurar uku ta COVID‑19. Ba a fayyace ainihin lokacin da aka yi allurar ba, don haka kada a ɗauka a matsayin jadawalin da aka tabbatar.
- Wanene zai iya amfana: manya masu shekaru sama da 65 da ke da lafiya gaba ɗaya kuma da tarihin rashin amsa allura. Fa'idar ta bayyana ne a cikin waɗanda ba su amsa allura ba, kuma ba a tantance hanya a likita ba don gano su. Gwajin antibodies bayan allura – wanda likita zai shirya – shi ne hanya mafi sauƙi don sanin matsayin ku.
- Mutanen da suka amsa allura da kyau: ba a nuna wani ƙarin amfani ba ga su.
- Mutanen da ke da raunin garkuwar jiki, masu karɓar transplant, ko waɗanda ke shan maganin rage garkuwa: wannan gwaji ya haɗa da manya masu lafiya, don haka ba a san tasirin ga su ba.
- Kowa da ke da cututtuka masu tsanani ko ke shan magunguna da yawa ya kamata ya tattauna da likita.
- Kowa da ke tunanin spermidine zai maye gurbin ƙarin allura ko shawarar likita: ba zai yi ba.
Abubuwan Da Ya Kamata Ka Kula Da Su
- Girman gwaji: mutane 40 ne kawai. Da aka raba su zuwa masu amsa da marasa amsa, ƙananan ƙungiyoyi sun ƙara wahalar da sakamako, don haka ba za a iya ɗaukar su a matsayin ƙarshe ba.
- Yanayin allura guda: duk mahalarta sun yi allurar SARS‑CoV‑2. Wataƙila ba za a iya amfani da sakamakon ga rigakafin mura, shingles ko pneumococcal ba.
- Antibodies da alamar ƙwayoyin sel, ba sakamakon klinik ba: an auna martani na garkuwa, ba a ga ko mutane sun kamuwa da cuta ba.
- Tsawon lokaci: makonni 13 ba su ba da wani bayani game da tasirin dogon lokaci ba.
- Rashin jituwa: wasu marubutan suna da alaƙa da The Longevity Labs da Oxford Healthspan, kamfanonin da ke da alaƙa da spermidine. Takarda ta bayyana cewa TLL ba su da hannu a ƙirƙirar gwaji, sakamakon, nazari ko rubutun takarda.
Gabaɗaya
Wannan gwaji ba ya tabbatar da cewa spermidine maganin ƙara tasirin allura ne. Yana ba da alamar kimiyya mai ma'ana: a manya da suka amsa ƙasa da ƙwarin ƙwaƙwalwa ga allura uku, 6 mg a rana na tsawon makonni 13 ya rage alamun senescence kuma ya inganta antibodies da memory B cells, tare da canji a ƙwayoyin da suka shafi autophagy. Mataki na gaba shi ne gwaji mafi girma, mai tsawo, da zai haɗa da allurori daban‑daban da ya mai da hankali kan sakamakon klinik. Har sai an sami wannan, spermidine ya kasance abin bincike mai alƙawari, ba magani da aka tabbatar ba.
